Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

[Allergic reaction to melphalan].

F Bleichner, S Mende

    Onkologie
    |August 1, 1982
    PubMed
    Summary
    This summary is machine-generated.

    Allergic reactions to melphalan are possible with both IV and oral routes. This study details a plasmocytoma patient who experienced an allergic reaction to intravenous melphalan but tolerated oral melphalan.

    Related Concept Videos

    You might also read

    Related Articles

    Articles linked to this work by shared authors, journal, and citation graph.

    Sort by
    Same author

    [Internet-based approaches in the therapy of eating disorders].

    Der Nervenarzt·2011
    Same author

    Association between cingulum bundle structure and cognitive performance: an observational study in major depression.

    European psychiatry : the journal of the Association of European Psychiatrists·2010
    Same author

    [Cognitive training in rehabilitation: a program to treat mild cognitive impairment].

    Zeitschrift fur Gerontologie und Geriatrie·2009
    Same author

    [Gene expression profiling of classic mitochondrial disorders. Its value in finding therapeutic strategies].

    Der Nervenarzt·2007
    Same author

    [Cognitive impairment, depression, and work capacity of 50-59-year-old psychosomatic inpatients].

    Der Nervenarzt·2005
    Same author

    [Patient treated with chemotherapy. Alarm signs requiring immediate intervention].

    MMW Fortschritte der Medizin·2001
    Same journal

    Successful treatment with nab-paclitaxel and gemcitabine after FOLFIRINOX failure in a patient with metastasized pancreatic adenocarcinoma.

    Onkologie·2013
    Same journal

    Metastatic germ cell tumour following renal transplantation.

    Onkologie·2013
    Same journal

    miR-145 inhibits proliferation and invasion of esophageal squamous cell carcinoma in part by targeting c-Myc.

    Onkologie·2013
    Same journal

    A meta-analysis of internal mammary lymph node metastasis in breast cancer patients.

    Onkologie·2013
    Same journal

    Patient-related delay in presentation for cutaneous squamous cell carcinoma. A cross-sectional clinical study.

    Onkologie·2013
    Same journal

    Treatment of primary breast cancer at the surgical unit of the Charité 1984-1998.

    Onkologie·2013
    See all related articles

    Area of Science:

    • Oncology
    • Pharmacology
    • Clinical Medicine

    Background:

    • Melphalan is a chemotherapy agent commonly used for treating multiple myeloma and ovarian cancer.
    • Known side effects include nausea, vomiting, and bone marrow suppression.
    • Allergic reactions to melphalan are less frequently reported but can occur.

    Observation:

    • This study reports on a patient diagnosed with plasmocytoma.
    • The patient experienced an allergic reaction following intravenous administration of melphalan.
    • The same patient was subsequently administered oral melphalan.

    Findings:

    • The patient tolerated oral melphalan without any adverse allergic reactions.
    • This suggests a potential difference in reaction profiles between intravenous and oral melphalan administration in certain patients.

    Related Experiment Videos

  • The findings highlight the importance of considering route-specific hypersensitivity.

    • Implications:

    • Clinicians should be aware of the possibility of allergic reactions to melphalan, regardless of administration route.
    • Further investigation into the mechanisms of melphalan hypersensitivity may be warranted.
    • Route de-escalation or switching may be a viable strategy for patients experiencing adverse reactions.